Literature DB >> 24464016

Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia.

Li Jia1, Andrew Clear, Feng-Ting Liu, Janet Matthews, Nadiha Uddin, Aine McCarthy, Elena Hoxha, Catherine Durance, Sameena Iqbal, John G Gribben.   

Abstract

Chronic lymphocytic leukemia (CLL) is a disease of an accumulation of mature B cells that are highly dependent on the microenvironment for maintenance and expansion. However, little is known regarding the mechanisms whereby CLL cells create their favorable microenvironment for survival. High-mobility group protein B-1 (HMGB1) is a highly conserved nuclear protein that can be actively secreted by innate immune cells and passively released by injured or dying cells. We found significantly increased HMGB1 levels in the plasma of CLL patients compared with healthy controls, and HMGB1 concentration is associated with absolute lymphocyte count. We therefore sought to determine potential roles of HMGB1 in modulating the CLL microenvironment. CLL cells passively released HMGB1, and the timing and concentrations of HMGB1 in the medium were associated with differentiation of nurse-like cells (NLCs). Higher CD68 expression in CLL lymph nodes, one of the markers for NLCs, was associated with shorter overall survival of CLL patients. HMGB1-mediated NLC differentiation involved internalization of both receptor for advanced glycation end products (RAGE) and Toll-like receptor-9 (TLR9). Differentiation of NLCs can be prevented by blocking the HMGB1-RAGE-TLR9 pathway. In conclusion, this study demonstrates for the first time that CLL cells might modulate their microenvironment by releasing HMGB1.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24464016      PMCID: PMC3954052          DOI: 10.1182/blood-2013-10-529610

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  49 in total

1.  Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases.

Authors:  A Taguchi; D C Blood; G del Toro; A Canet; D C Lee; W Qu; N Tanji; Y Lu; E Lalla; C Fu; M A Hofmann; T Kislinger; M Ingram; A Lu; H Tanaka; O Hori; S Ogawa; D M Stern; A M Schmidt
Journal:  Nature       Date:  2000-05-18       Impact factor: 49.962

Review 2.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

3.  Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma.

Authors:  Sandro Jube; Zeyana S Rivera; Marco E Bianchi; Amy Powers; Ena Wang; Ian Pagano; Harvey I Pass; Giovanni Gaudino; Michele Carbone; Haining Yang
Journal:  Cancer Res       Date:  2012-05-02       Impact factor: 12.701

Review 4.  HMGB1 and RAGE in inflammation and cancer.

Authors:  Gary P Sims; Daniel C Rowe; Svend T Rietdijk; Ronald Herbst; Anthony J Coyle
Journal:  Annu Rev Immunol       Date:  2010       Impact factor: 28.527

5.  The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.

Authors:  Yair Herishanu; Patricia Pérez-Galán; Delong Liu; Angélique Biancotto; Stefania Pittaluga; Berengere Vire; Federica Gibellini; Ndegwa Njuguna; Elinor Lee; Lawrence Stennett; Nalini Raghavachari; Poching Liu; J Philip McCoy; Mark Raffeld; Maryalice Stetler-Stevenson; Constance Yuan; Richard Sherry; Diane C Arthur; Irina Maric; Therese White; Gerald E Marti; Peter Munson; Wyndham H Wilson; Adrian Wiestner
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

Review 6.  Immunogenic cell death and DAMPs in cancer therapy.

Authors:  Dmitri V Krysko; Abhishek D Garg; Agnieszka Kaczmarek; Olga Krysko; Patrizia Agostinis; Peter Vandenabeele
Journal:  Nat Rev Cancer       Date:  2012-11-15       Impact factor: 60.716

7.  HMGB1 is an endogenous immune adjuvant released by necrotic cells.

Authors:  Patrizia Rovere-Querini; Annalisa Capobianco; Paola Scaffidi; Barbara Valentinis; Federica Catalanotti; Marta Giazzon; Ingrid E Dumitriu; Susanne Müller; Matteo Iannacone; Catia Traversari; Marco E Bianchi; Angelo A Manfredi
Journal:  EMBO Rep       Date:  2004-07-23       Impact factor: 8.807

8.  Tumor-derived monocyte chemoattractant protein-1 induces intratumoral infiltration of monocyte-derived macrophage subpopulation in transplanted rat tumors.

Authors:  S Yamashiro; M Takeya; T Nishi; J Kuratsu; T Yoshimura; Y Ushio; K Takahashi
Journal:  Am J Pathol       Date:  1994-10       Impact factor: 4.307

Review 9.  STATs in cancer inflammation and immunity: a leading role for STAT3.

Authors:  Hua Yu; Drew Pardoll; Richard Jove
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716

10.  Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas.

Authors:  Y Komohara; K Ohnishi; J Kuratsu; M Takeya
Journal:  J Pathol       Date:  2008-09       Impact factor: 7.996

View more
  51 in total

1.  Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia.

Authors:  Stefania Fiorcari; Silvia Martinelli; Jenny Bulgarelli; Valentina Audrito; Patrizia Zucchini; Elisabetta Colaci; Leonardo Potenza; Franco Narni; Mario Luppi; Silvia Deaglio; Roberto Marasca; Rossana Maffei
Journal:  Haematologica       Date:  2014-11-14       Impact factor: 9.941

2.  Reactive oxygen species regulate the differentiation of acute promyelocytic leukemia cells through HMGB1-mediated autophagy.

Authors:  Liangchun Yang; Wenwen Chai; Yanping Wang; Lizhi Cao; Min Xie; Minghua Yang; Rui Kang; Yan Yu
Journal:  Am J Cancer Res       Date:  2015-01-15       Impact factor: 6.166

Review 3.  Haematological malignancies: at the forefront of immunotherapeutic innovation.

Authors:  Pavan Bachireddy; Ute E Burkhardt; Mohini Rajasagi; Catherine J Wu
Journal:  Nat Rev Cancer       Date:  2015-03-19       Impact factor: 60.716

Review 4.  Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia.

Authors:  Noelia Purroy; Catherine J Wu
Journal:  Cold Spring Harb Perspect Med       Date:  2017-04-03       Impact factor: 6.915

5.  Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL.

Authors:  Kallesh D Jayappa; Craig A Portell; Vicki L Gordon; Brian J Capaldo; Stefan Bekiranov; Mark J Axelrod; L Kyle Brett; Julia D Wulfkuhle; Rosa I Gallagher; Emanuel F Petricoin; Timothy P Bender; Michael E Williams; Michael J Weber
Journal:  Blood Adv       Date:  2017-06-13

6.  Overexpression of HMGB1 A-box reduced lipopolysaccharide-induced intestinal inflammation via HMGB1/TLR4 signaling in vitro.

Authors:  Fu-Cai Wang; Jing-Xuan Pei; Jun Zhu; Nan-Jin Zhou; Dong-Sheng Liu; Hui-Fang Xiong; Xiao-Qun Liu; Dong-Jia Lin; Yong Xie
Journal:  World J Gastroenterol       Date:  2015-07-07       Impact factor: 5.742

Review 7.  B cells and macrophages pursue a common path toward the development and progression of chronic lymphocytic leukemia.

Authors:  G Galletti; F Caligaris-Cappio; M T S Bertilaccio
Journal:  Leukemia       Date:  2016-09-28       Impact factor: 11.528

Review 8.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08

9.  Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo.

Authors:  B S Hanna; F McClanahan; H Yazdanparast; N Zaborsky; V Kalter; P M Rößner; A Benner; C Dürr; A Egle; J G Gribben; P Lichter; M Seiffert
Journal:  Leukemia       Date:  2015-11-02       Impact factor: 11.528

10.  Arresting the Inflammatory Drive of Chronic Lymphocytic Leukemia with Ibrutinib.

Authors:  Pavan Bachireddy; Catherine J Wu
Journal:  Clin Cancer Res       Date:  2016-02-04       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.